FDA.reportPublic FDA data

tralokinumab-ldrm 300 MG in 2 ML Auto-Injector

RxCUI
2686061
RxNorm name
tralokinumab-ldrm 300 MG in 2 ML Auto-Injector
Display name
tralokinumab-ldrm 300 MG in 2 ML Auto-Injector
Full name
tralokinumab-ldrm 300 MG in 2 ML Auto-Injector
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:23

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761180Adbrytralokinumab-ldrm351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AdbryTRALOKINUMAB-LDRMLEO Pharma Inc.d8020b69-3001-44e2-9b5d-5f93d9aaf6e12025-12-17Warnings, Adverse reactionsExact identifier
rxcui: 2686061

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
d8020b69-3001-44e2-9b5d-5f93d9aaf6e1tralokinumab-ldrm 300 MG in 2 ML Auto-InjectorPSN15These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 202120251217
d8020b69-3001-44e2-9b5d-5f93d9aaf6e1tralokinumab-ldrm 300 MG per 2 ML Auto-InjectorSY15These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 202120251217
d8020b69-3001-44e2-9b5d-5f93d9aaf6e12 ML tralokinumab-ldrm 150 MG/ML Auto-InjectorSCD15These highlights do not include all the information needed to use ADBRY safely and effectively. See full prescribing information for ADBRY. ADBRY ® (tralokinumab-ldrm) injection, for subcutaneous use Initial U.S. Approval: 202120251217